Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$20.17 - $23.93 $15,228 - $18,067
755 Added 3.98%
19,734 $468,000
Q4 2023

Feb 09, 2024

SELL
$19.25 - $24.13 $58,674 - $73,548
-3,048 Reduced 13.84%
18,979 $455,000
Q3 2023

Nov 09, 2023

BUY
$19.04 - $22.74 $70,657 - $84,388
3,711 Added 20.26%
22,027 $481,000
Q2 2023

Aug 04, 2023

SELL
$18.17 - $20.48 $194,328 - $219,033
-10,695 Reduced 36.87%
18,316 $350,000
Q1 2023

May 12, 2023

SELL
$16.3 - $19.41 $352,666 - $419,954
-21,636 Reduced 42.72%
29,011 $563,000
Q4 2022

Feb 03, 2023

BUY
$14.96 - $17.39 $448,470 - $521,317
29,978 Added 145.04%
50,647 $812,000
Q1 2022

May 06, 2022

BUY
$17.03 - $22.67 $351,993 - $468,566
20,669 New
20,669 $469,000
Q1 2021

May 07, 2021

SELL
$20.53 - $25.22 $582,579 - $715,667
-28,377 Closed
0 $0
Q4 2020

Feb 05, 2021

BUY
$18.39 - $24.8 $138,973 - $187,413
7,557 Added 36.3%
28,377 $570,000
Q3 2020

Oct 30, 2020

SELL
$20.67 - $26.94 $142,788 - $186,101
-6,908 Reduced 24.91%
20,820 $509,000
Q2 2020

Jul 31, 2020

SELL
$16.46 - $27.42 $137,539 - $229,121
-8,356 Reduced 23.16%
27,728 $658,000
Q1 2020

May 01, 2020

BUY
$14.46 - $21.8 $521,774 - $786,631
36,084 New
36,084 $621,000
Q3 2019

Nov 01, 2019

SELL
$17.68 - $22.65 $261,717 - $335,287
-14,803 Closed
0 $0
Q2 2019

Aug 02, 2019

SELL
$18.93 - $24.75 $7,893 - $10,320
-417 Reduced 2.74%
14,803 $316,000
Q1 2019

May 03, 2019

BUY
$19.6 - $24.76 $298,312 - $376,847
15,220 New
15,220 $362,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track Richard Pzena's Portfolio

Track Richard Pzena Portfolio

Follow Richard Pzena (Pzena Investment Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pzena Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pzena Investment Management LLC and Richard Pzena with notifications on news.